PHAL: Losses increased as net sales stayed at zero; new capital extends operations but debt remains

About this update from Pharmalundensis Ab

Net sales remained at zero, with losses deepening year-over-year. A recent share issue raised 3.13 million SEK, funding operations into next year but not covering all debt. Focus is on demonstrating the new Förevaporeringsenheten and securing further financing for clinical trials.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Pharmalundensis Ab